New York, July 13, 2026, 17:11 (EDT)
Pfizer NYSE:PFE added 1.28% to $24.48 in post-market trading Monday. The stock outperformed the broader market and two other major pharma names while investors moved out of risk on worries about rising U.S.-Iran tensions, higher oil, and chip stocks selling off. The NYSE closed the regular session at 4 p.m. EDT, but after-hours trading was still open when this was published.
| Asset | Monday move | Pfizer’s return lead |
|---|---|---|
| Pfizer NYSE:PFE | +1.28% | — |
| Merck NYSE:MRK | up 0.40% | lags by 0.88 percentage point |
| Johnson & Johnson NYSE:JNJ | up 0.34% | trails by 0.94 percentage point |
| S&P 500 | fell 0.79% | leads by 2.07 percentage points |
| Nasdaq Composite | dropped 1.55% | ahead by 2.83 percentage points |
Pfizer’s lead is based on equity prices after the close and closes for the official indexes, according to Reuters.
Pfizer just got pitched as a way to hedge AI bets with some cash yield, according to an investor note over the weekend. Monday’s session gave that call a real test. The board stuck to its $0.43 quarterly dividend, or $1.72 a share annualized, giving Pfizer stock an indicated yield near 7.0%. Investors will see if sales and cash flow back up the payout when second-quarter numbers come out August 4.
Options traders kept a more careful stance than the stock itself. Around 128,000 contracts changed hands, with calls ahead of puts but the put/call ratio hitting 0.81, versus a typical 0.59. Puts pay if the stock drops; calls win if it rises. That ratio ran 37% above normal. Implied volatility showed the market bracing for a daily move of $0.36, or 1.5% of the share price. The tilt stayed moderately bullish, but traders paid up for protection.
That gap didn’t show up in last Monday’s session. Pfizer dropped 2.47% to $23.72 on July 6, while the S&P 500 rose 0.72%. Since then, up to Monday after hours, Pfizer gained around 3.2% as the index gave up about 0.3%. That’s a relative shift of roughly 3.5 points. The move looks more like a turn toward income than a change in how markets see Pfizer’s long-term profit outlook.
The math on the dividend is what draws investors, but it also puts a ceiling on how much room there is for a letdown. Pfizer uses adjusted earnings per share as its non-GAAP profit figure, stripping out certain items from what’s reported. GAAP is standard U.S. accounting.
| Dividend and earnings measure | Figure | Investor implication |
|---|---|---|
| Annualised dividend | $1.72 a share | Yield around 7.0% based on $24.48 price |
| 2026 adjusted EPS guidance | $2.80-$3.00 | Payout eats up 57%-61% of earnings |
| Q1 cash dividends | $2.4 billion | About 89% of net income ($2.687 billion) paid out |
| 2026 share repurchases | None assumed | No buybacks to lift EPS |
Payout ratios use Pfizer’s published guidance and Q1 numbers. Pfizer said repurchases might start again once it reduces leverage.
Fresh target moves on Wall Street show valuations have support but execution worries linger. Bank of Montreal’s NYSE:BMO BMO Capital Markets lowered its price target to $30 from $34 but kept an Outperform, while Guggenheim trimmed its target to $35 from $36, keeping its Buy. Those new targets suggest upside of about 23% and 43% from Monday’s close. BMO said the sentiment rebound may fade unless second-quarter commercial results are strong.
Friday’s U.S. approval for Padcev, which Pfizer and Astellas Pharma (TYO:4503) developed together, looks like the biggest growth driver. The drug, combined with Merck’s Keytruda, is now cleared for use before and after surgery in muscle-invasive bladder cancer. The Phase 3 trial showed the combo cut the risk of recurrence, progression or death by 47%, and lowered the risk of death by 35%. After two years, 79.4% of patients on the regimen were alive without an event, against 66.2% for those getting chemotherapy. Christopher Hoimes of the Duke Cancer Institute, who ran the study, said this approach could “significantly reduce the risk of recurrence and improve overall survival.” Serious or severe adverse events hit 75.7% of patients on the combo, versus 67.2% on chemo. Pfizer
Padcev is already one of Pfizer’s faster-growing drugs. First-quarter sales rose 39% operationally, stripping out currency moves. Pfizer’s launched and acquired medicines climbed 22% in the quarter, which helped make up for less COVID-product revenue. JPMorgan Chase NYSE:JPM analyst Chris Schott said the pipeline “could make the story more interesting over time,” but said investors still want more clinical data and less development risk to get more positive. Yahoo Finance
The bear case still looks real. The higher side-effect load might slow how fast doctors use the new bladder-cancer regimen, and a failed Phase 3 trial in lung cancer for sigvotatug vedotin has already shaken faith in Pfizer’s oncology pipeline. HSBC Holdings NYSE:HSBC analyst Rajesh Kumar downgraded the shares to Hold and now sees just a 40% chance the drug makes it to market, citing a “paucity of short-term re-rating catalysts” that could lift the stock. A weak Q2 cash result or softer outlook could mean the 7% yield just rewards lack of growth, not safety. TipRanks
August 4 now becomes the key date. Investors are looking for signs that the Padcev launch is actually driving sales, that earnings are enough to cover the dividend, and that full-year guidance hasn’t been cut. On Monday, Pfizer showed it can add more to an AI-focused portfolio even in a choppy market. But higher demand for downside protection says the market isn’t convinced this defensive move is a real shift back to growth.
Related articles: NYSE:PFE
